DexCom recently reported preliminary fourth-quarter results showing year-over-year revenue growth in both U.S. and ...

New CEO of Dexcom, Jake Leach, joined MobiHealthNews at the JPM Healthcare Conference to discuss his leadership priorities, ...

SAN DIEGO--(BUSINESS WIRE)--This World Diabetes Day, DexCom, Inc. (NASDAQ: DXCM), the global leader in glucose biosensing technology, is encouraging people with diabetes globally to take the first ...

If you are wondering whether DexCom's current share price really reflects what you are getting for your money, you are not alone. The stock last closed at US$73.67, with returns of 4.2% over 7 days, 9 ...

Often, when dealing with fast-growing companies trading at what seem to be elevated multiples, I add that the margin of error is small. After all, a high valuation ...

Dexcom launched its first over-the-counter continuous glucose monitor called Stelo on Monday. Users can buy a one-month supply online for $99, or sign up for an ongoing subscription at $89 a month.

Dexcom achieved FY25 revenues of around $4.66bn, corresponding to a 16% uplift over FY24.

Deep-pocketed investors have adopted a bearish approach towards DexCom (NASDAQ:DXCM), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled ...

A top healthcare stock to own over the years has been DexCom (NASDAQ: DXCM). The company makes continuous glucose monitors (CGMs) that help diabetics track their glucose levels. CGMs are necessary ...

DexCom Inc (NASDAQ:DXCM) is one of the 12 best Medical Devices stocks to invest in according to Hedge Funds. As of the January 28 closing, DexCom Inc. (NASDAQ:DXCM) had highly bullish sentiment ...

Supermodel Bambi Northwood-Blyth wears a Dexcom glucose monitor. So does your next-door neighbor with Type 2 diabetes and your fit-fluencer friend. Jake Leach, who took over as Dexcom CEO today, wants ...